| Intuniv (guanfacine XR) / Shionogi, Takeda |
NCT00152009: Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17 |
|
|
| Completed | 3 | 345 | NA | SPD503 (Guanfacine hydrochloride) (2 mg), SPD503 (3 mg), SPD503 (4 mg), Placebo | Shire | Attention Deficit Disorder With Hyperactivity | 08/03 | 08/03 | | |
NCT00150618: Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17 |
|
|
| Completed | 3 | 324 | NA | SPD503 (1 mg), Guanfacine hydrochloride, SPD503 (2 mg), SPD503 (3 mg), SPD503 (4 mg), Placebo | Shire | Attention Deficit Disorder With Hyperactivity | 10/04 | 10/04 | | |
NCT00367835: SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms |
|
|
| Completed | 3 | 217 | US | SPD503 (Guanfacine hydrochloride), Placebo | Shire | ADHD | 01/08 | 01/08 | | |
NCT00734578: Efficacy and Safety of SPD503 in Combination With Psychostimulants |
|
|
| Completed | 3 | 461 | US | SPD503-AM, Intuniv, SPD503-PM, Placebo | Shire | ADHD | 12/09 | 12/09 | | |
NCT00997984: Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study) |
|
|
| Completed | 3 | 340 | Canada, US | extended-release guanfacine hydrochloride (SPD503), Intuniv, placebo, extended-release guanfacine hydrochloride | Shire | Attention-Deficit/Hyperactivity Disorder | 10/10 | 10/10 | | |
NCT01244490 / 2010-018579-12: Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 3 | 338 | Europe, Canada, US, RoW | Extended-release Guanfacine Hydrochloride, Intuniv, Atomoxetine Hydrochloride, Strattera, Placebo Comparator | Shire | Attention Deficit Hyperactivity Disorder | 05/13 | 05/13 | | |
NCT01081132 / 2011-002221-21: Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl |
|
|
| Completed | 3 | 314 | US | Extended-release Guanfacine Hydrochloride, Intuniv, Placebo | Shire | Attention-Deficit/Hyperactivity Disorder | 05/13 | 05/13 | | |
NCT01081145 / 2009-018161-12: Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 3 | 528 | Europe, Canada, US | Extended-release Guanfacine Hydrochloride, Placebo | Shire | Attention-deficit/Hyperactivity Disorder | 06/13 | 06/13 | | |
SPD503-315, NCT03662763: Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity |
|
|
| Completed | 3 | 12 | Europe | Extended-release Guanfacine Hydrochloride (SPD503), Extended-release Guanfacine Hydrochloride, SPD503, Placebo oral capsule | Maastricht University Medical Center, Shire | Attention Deficit Disorder | 08/13 | 12/13 | | |
NCT01500694 / 2011-004668-31: Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe |
|
|
| Completed | 3 | 215 | Europe, RoW | Extended-release Guanfacine HCl (Intuniv, SPD503), Intuniv, SPD503 | Shire | Attention Deficit Hyperactivity Disorder (ADHD) | 09/15 | 09/15 | | |
| Active, not recruiting | 3 | 148 | Europe | Guanfacine, Placebo | Imperial College London | Alzheimer Disease | 08/24 | 08/24 | | |
